What Is Ozempic?

Ozempic is the branded name for semaglutide manufactured by Novo Nordisk, delivered via a pre-filled, multi-dose injector pen. It was approved by the US FDA in December 2017 and subsequently by India's Central Drugs Standard Control Organisation (CDSCO) for the treatment of type 2 diabetes in adults.

Ozempic contains semaglutide — a GLP-1 receptor agonist — at doses of 0.5mg and 1mg for diabetes management. The pen format allows once-weekly subcutaneous self-injection. Because the pen is convenient, well-tolerated, and delivers clinically meaningful weight loss alongside glycemic control, demand in India has grown substantially — even among people without diabetes who use it off-label for weight management.

Ozempic vs Wegovy — Same Drug, Different Jobs

This distinction confuses many patients. Both Ozempic and Wegovy contain the identical molecule: semaglutide. The differences are regulatory and dosing-based:

Because Ozempic (1mg max) delivers a lower peak semaglutide exposure than Wegovy (2.4mg), its weight loss is proportionally smaller. However, many Indian physicians prescribe Ozempic off-label and titrate toward 2.4mg equivalence using available pens — achieving Wegovy-equivalent outcomes.

How to Inject Ozempic

Ozempic comes as a pre-filled pen requiring very small needles (4mm × 32G, sold separately). The injection process:

1. Choose an injection site: abdomen (2 inches from navel), outer thigh, or upper arm
2. Clean the skin with an alcohol swab and allow to dry
3. Attach a new needle to the pen, dial the dose
4. Pinch the skin gently, insert needle at 90°, inject slowly and hold for 6 seconds
5. Remove needle and dispose in a sharps container
6. Rotate injection sites each week to prevent lipohypertrophy (hard lumps under skin)

Storage in India: Unopened pens must be refrigerated at 2–8°C. Once opened, store at room temperature below 30°C for up to 56 days. Never freeze. In Indian summer conditions, transport in an insulated bag with an ice pack — prolonged heat exposure above 30°C degrades the peptide.

Cardiovascular Benefits Beyond Weight Loss

Ozempic's cardiovascular data is one of its most compelling features. The SUSTAIN-6 trial (PubMed) showed a 26% relative risk reduction in major adverse cardiovascular events (MACE) in high-risk T2D patients compared to placebo — including non-fatal MI and non-fatal stroke. This benefit was partially, but not entirely, explained by weight loss and HbA1c improvement.

The SELECT trial (2023) extended this finding to people without diabetes who had pre-existing cardiovascular disease: semaglutide 2.4mg reduced MACE by 20% over 3.3 years. This was the first trial to demonstrate cardiovascular benefit from a GLP-1 agonist in a non-diabetic obese population.

Comparison: Ozempic vs Wegovy vs Mounjaro

Who Should Take Ozempic?

Ozempic is most appropriate for:

• Adults with type 2 diabetes not adequately controlled on metformin alone
• T2D patients with established cardiovascular disease who need proven MACE reduction
• Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities — prescribed off-label or via Wegovy indication
• Patients with metabolic syndrome or NASH where insulin resistance is a core problem

Ozempic is not appropriate for: pregnant or breastfeeding women, people with personal/family history of medullary thyroid carcinoma or MEN2, or those with active pancreatitis.

The Muscle Loss Concern and How to Address It

A critical underappreciated issue: on semaglutide, approximately 25–40% of the weight lost comes from lean mass (muscle), not just fat. For longevity, muscle mass is one of the strongest predictors of metabolic health, insulin sensitivity, and healthy aging. Losing it while losing fat is a poor trade if muscle preservation is neglected.

The countermeasure is straightforward but requires commitment:

• Protein: 1.2–1.6g/kg body weight daily — prioritise eggs, paneer, whey protein, tofu, chicken. This is harder on reduced appetite but non-negotiable for lean mass preservation.
• Creatine monohydrate 3–5g/day — the most evidence-backed supplement for preserving lean mass during caloric restriction. No loading phase needed; just take daily.
• Resistance training 2–3x/week — provides the anabolic signal that tells the body to spare muscle even in a caloric deficit.

Biomarker Connections

Ozempic's effects are measurable across multiple biomarker categories:

• HbA1c: Expect 1–2% reduction from baseline in T2D patients. Target below 6.5%.
• Fasting insulin / HOMA-IR: Improved insulin sensitivity typically visible at 12 weeks
• ApoB and LDL-C: Modest improvement (5–10% LDL reduction); triglycerides improve more substantially
• Body weight and waist circumference: Primary efficacy markers — track monthly
• Liver enzymes (ALT/AST): Often improve with weight loss, particularly in fatty liver
• B12: Monitor annually — dietary restriction can deplete over 12–18 months

Frequently Asked Questions

Related Terms